Tuvusertib
As of the edition of 20 October 2026, Tuvusertib is a small molecule: in active development; acts on ATR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 16, 2 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Inherited and neonatal; Nervous system; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ATR | Serine/threonine-protein kinase ATR | Q13535 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 2 | 4 | 1 |
| Phase 2 | 9 | 2 | 6 | 1 |
| All trials | 16 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck KGaA | Lead sponsor of trials | 2019 to now |
| Merck Healthcare KGaA | Lead sponsor of trials | 2024 to now |